Swiss National Bank Solid Biosciences Inc. Transaction History

Swiss National Bank

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 05, 2020	SELL	$2.1 - $3.42 $83,160 - $135,432	-39,600 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$2.82 - $12.9 $32,147 - $147,060	11,400 Added 40.43%	39,600 $176,000
Q4 2018 Feb 13, 2019	BUY	$21.32 - $46.34 $601,224 - $1.31 Million	28,200 New	28,200 $756,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $40.5M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.